Background: The development of alternative control measures, such as phage therapy or adjunctive therapy, is urgently needed to manage the dissemination of carbapenemase-producing *Klebsiella pneumoniae*. 

Objective: This study aimed to evaluate the therapeutic potential of formulated phage cocktails and their interaction with select antibiotics in inhibiting the growth of carbapenemase-producing *K. pneumoniae* clinical isolate in vitro in Kenya.

Methods: The study was conducted from February 2021 to October 2021 at the Institute of Primate Research, Nairobi, Kenya. Phage cocktails were formulated based on the morphology and biological properties of precipitated *Klebsiella* phages. The efficacy of individual bacteriophages and phage cocktails as well as their combination with antibiotics were determined for their inhibitory activity on carbapenemase-producing *K. pneumoniae* (KP20).

Results: The precipitated bacteriophages were members of *Myoviridae, Siphoviridae* and *Podoviridae*. Regarding the evaluation of the phage cocktails, the absorbances at 600 nm of the bacterial culture treated with the two-phage cocktail (2φ MA) ranged from 0.173 to 0.246 at 16 h and 20 h whereas it peaked from 2.116 to 2.190 for the positive control. Moreover, the results of the adjunctive therapy showed that the optical density at 600 nm of the bacterial culture treated with 2φ MA was 0.186 at 24 h post-incubation time while it was 0.099 with the bacterial culture treated with imipenem in combination with 2φ MA.

Conclusion: This study demonstrated that the two-phage cocktail in combination with imipenem was able to synergistically delay the increase in carbapenemase-producing *K. pneumoniae* growth in vitro.

Keywords: phage cocktail; antibiotics; *Klebsiella pneumoniae*; carbapenemase; absorbances.

Introduction

The development of alternative control measures is urgently needed to manage the dissemination of carbapenemase-producing (CP) *Klebsiella pneumoniae* because of the decrease in the effectiveness of antibiotic drugs.\(^1,2\) Bacteriophage therapy has, therefore, been proposed as an alternative strategy in controlling multidrug-resistant (MDR) bacterial infections, including MDR *K. pneumoniae* clinical isolates.\(^3,4\) Some of the beneficial effects of bacteriophages over antibiotics include their abundance, host specificity and exponential replication.\(^5\) However, the narrowness of phage host range and the ever emergence of novel pathogen variants will at minimum represent some limitations for phage therapy.\(^6,7\) This challenge can be managed by formulating phage cocktails that contain different phages infecting one species or by combining phages with antibiotics, which may result in a broad spectrum of activity.\(^8\) The characterisation of therapeutic phages in terms of their biology and bactericidal...
activity is mandatory before any preclinical trials because the application of non-characterised lytic bacteriophages may cause undesirable virulence as an adaptive response to bacteriophage infection.\textsuperscript{5,9} In other words, the development of effective strategies, such as phage growth parameters, host range spectrum, the presence of lytic proteins, formulation of phage cocktail and phage synergistic interaction with antibiotic to enhance phage efficacy, is a key prerequisite for optimal treatment of MDR infections caused by \textit{K. pneumoniae}. Several studies have reported the advantages and drawbacks of phage cocktails in treating MDR bacteria.\textsuperscript{10,11} Unfortunately, bacteriophages employed as cocktail or adjunctive therapy have not been well investigated in the African continent to effectively control MDR bacterial infections.\textsuperscript{12} This study aimed to evaluate the therapeutic potential of formulated phage cocktails and their interaction with select antibiotics in inhibiting the growth of CP \textit{K. pneumonia} clinical isolate in vitro in Kenya.

**Methods**

**Ethical considerations**

This study was not human or animal research. However, clearance was issued by the Nairobi City Water & Sewerage Company Limited (NCWSC/HR/TRG.14/Vol.8/14/MMM/ak) for collection of waste water samples.

**Bacterial isolate collection, phage isolation and purification**

The study was conducted from February 2021 to October 2021 in the Phage Biology Research Laboratory at the Institute of Primate Research, Nairobi, Kenya. The clinical isolate of CP \textit{K. pneumoniae} (KP20) was obtained from the stock of the recently published data in Kenya.\textsuperscript{13} Bacteriophages were isolated from waste water samples of Dandora Estate Sewage Treatment Works (Ruai) and Rongai effluent, Nairobi, Kenya. They were purified from waste water samples through spot assay and double-layer plaque method as described, previously.\textsuperscript{14,15}

**Determination of minimum inhibitory concentrations for KP20**

The minimum inhibitory concentrations of a panel of antibiotics including carbapenems for KP20 were determined using VITEK 2 Systems version 9.2 and AST-XN05 (bar code 1481424403205844) card (BioMerieux, Inc., Hazelwood, Missouri, United States), according to the manufacturer’s instructions. The detailed procedure is described in online Supplementary Method 1.

**Bacteriophage propagation and precipitation**

Phage lysate (≥ 10\textsuperscript{8} PFU/mL or 10\textsuperscript{9} PFU/mL) was propagated in large volume, concentrated and cleaned up in the presence of sodium chloride and polyethylene glycol as described elsewhere.\textsuperscript{14,16}

**Morphological characterisation of precipitated bacteriophages**

The morphological characterisation of the precipitated \textit{Klebsiella} phages was conducted at the University of Leicester, United Kingdom. Negative staining with 1% (weight/volume) uranyl acetate on 3 mm carbon-coated copper grids of the precipitated \textit{Klebsiella} phages was conducted at the University of Leicester and the bacteriophages were visualised with a transmission electron microscope (JEOL UK Ltd., Welwyn Garden City, United Kingdom).\textsuperscript{17} Bacteriophages were then classified according to their morphology.\textsuperscript{18}

**Bacteriophage host range determination**

A spot assay was conducted to determine the host range of precipitated bacteriophages and phage cocktails as described by Kutter.\textsuperscript{19} Bacterial strains tested in our study included reference strains and MDR bacterial strains reported by Michodigni et al.\textsuperscript{13} and described in online Supplementary Methods 2.

**One-step growth experiment**

A one-step growth experiment for determination of latent period, and burst size of precipitated bacteriophages, was performed as described elsewhere, with some modifications.\textsuperscript{20} Exponential-growth-phase culture of CP \textit{K. pneumoniae} (≥ 2.98 × 10\textsuperscript{8} CFU/mL) and phage precipitate (≥ 10\textsuperscript{8}–10\textsuperscript{10} PFU/mL) were mixed with bacterial suspension to obtain a multiplicity of infection (MOI) of 0.1.\textsuperscript{14} The suspension was incubated at 37 °C in a shaking incubator for 10 min at 120 rotations per minute following with centrifugation. The pellet was then suspended in 7 mL of fresh tryptic soy broth and incubated at 37 °C in a shaking incubator at 125 rotations per minute. At 3-min intervals, from 0 min to 36 min, 500 µL of the suspension was taken and phage titres were estimated.\textsuperscript{20,21}

**Formulation of phage cocktails and evaluation of their in vitro activity on carbapenemase-producing \textit{Klebsiella pneumoniae}**

Three \textit{Klebsiella} phages, designated as CPRSA, CPRSB and ESBLA, were used for the formulation of two-phage cocktail (2φ MA) and three-phage cocktail (3φ MB). The two-phage cocktail comprised CPRSA and CPRSB while the three-phage cocktail consisted of CPRSA, CPRSB and ESBLA. Bacteriophage cocktails consisting of two and three tested phage lysates were formulated by combining in equal ratios of 1:1 and 1:1:1. The evaluation of the phage cocktails’ effectiveness was carried out based on the method described by Merabishvili with some modifications.\textsuperscript{22} Two-phage (2φ MA) and three-phage (3φ MB) cocktails were composed and their ability to inhibit the growth of KP20 at its exponential-growth-phase was evaluated. Subsequently, the efficacy of two individual bacteriophages, designated as \textit{Klebsiella} phage CPRSA and CPRSB at MOI 1.0, 0.1 and 0.001, was also investigated. Only broth media (tryptic soy broth) and individual bacteriophages represented the negative controls. Bacterial culture with a final resulting concentration of
Evaluation of inhibitory activity of phage cocktails in combination with antibiotics on carbapenemase-producing *Klebsiella pneumoniae* in vitro

The inhibitory activity of the phage cocktail alone, and in combination with imipenem or tigecycline was assessed on KP20 at its optimal exponential growth (OD<sub>600</sub> = 0.6). The two antibiotics meropenem and tigecycline (Glentham Life Sciences Ltd. Wiltshire, United Kingdom) were tested in combination with 2φ MA and 3φ MB. The phage cocktails 2φ MA and 3φ MB with optimal concentrations (MOI 0.1 and 0.001) were used in this experiment in combination with the single and double of the minimum inhibitory concentrations of imipenem and tigecycline. Sterile broth media (tryptic soy broth), bacterial culture treated with antibiotics, and bacteriophage cocktails represented the negative controls. Bacterial culture with a final resulting concentration of ≈ 2.98 × 10<sup>8</sup> CFU/mL served as a positive control sample. The growth of the host bacterium was monitored at 3-h intervals, between 0 h and 24 h, and at 48 h of incubation by measuring OD<sub>600</sub>. The optical densities obtained at 600 nm were compared to the ones of positive and negative control samples. The different concentrations of phage cocktails and antibiotics are indicated in online Supplementary Table 2. The experiment was performed in duplicate.

**Results**

**Minimum inhibitory concentrations of antibiotics and detected carbapenemase genes**

The minimum inhibitory concentrations of imipenem and tigecycline to KP20 were 4 μg/mL and 1 μg/mL (Table 1). We previously reported the presence of extended-spectrum beta-lactamase (ESBL) genes (blaTEM and blaOXA) and carbapenemase genes (blaNDM-1, blaIMP). The ESBL and carbapenemase genes produced by KP20 are indicated in Table 1.

**Morphological characteristics of precipitated *Klebsiella* phages**

A transmission electron microscope showed that the bacteriophages included in this cocktail were all tailed phages (Figure 1). Among the three imaged bacteriophages, two were myoviruses (CPRSA and CPRSB) and one was a podovirus (ESBLA).

**Precipitated *Klebsiella* phages growth characteristics**

The burst sizes of the precipitated phages in the cocktail were 610 (1.812 × 10<sup>15</sup> ÷ 2.98 × 10<sup>8</sup>), 1 (2.294 × 10<sup>6</sup> ÷ 2.98 × 10<sup>5</sup>) and 10 (3.123 × 10<sup>6</sup> ÷ 2.98 × 10<sup>4</sup>) for *Klebsiella* phage CPRSA, CPRSB, and ESBLA. Regarding their latent period, *Klebsiella* phages CPRSA and CPRSB had the same latent period (9 min) and the one of ESBLA was 18 min as shown in online Supplementary Figure 1.

**Table 1** Minimum inhibitory concentrations of a panel of antibiotic and carbapenemase produced to KP20, Nairobi, Kenya, February 2021 – October 2021.

| Antibiotic family | Antibiotic agent | MIC (μg/mL) | Detected phenotypes | Detected genotypes†‡ |
|-------------------|------------------|-------------|---------------------|----------------------|
| Beta-lactams      | Ticarcillin/Clavulanic | ≥ 128       | Production of carbapenemase | blaTEM and blaOXA† |
|                   | Piperacillin      | ≥ 128       |                      | blaNDM-1, blaIMP‡ |
|                   | Cefuroxime        | ≥ 64        |                      |                     |
|                   | Cefuroxime Axetil | ≥ 64        |                      |                     |
|                   | Ceftaxime         | ≥ 4         |                      |                     |
|                   | Ceftriaxone       | ≥ 64        |                      |                     |
|                   | Cefepime          | ≥ 64        |                      |                     |
|                   | Aztreonam         | ≥ 64        |                      |                     |
|                   | Meropenem         | ≥ 16        |                      |                     |
|                   | Imipenem          | ≥ 4         |                      |                     |
| Quinolones        | Levofloxacin      | ≥ 8         | Resistant            | NA                   |
|                   | Moxifloxacin      | ≥ 8         |                      | NA                   |
| Tetracyclines     | Minocycline       | 8           | Intermediate         |                      |
|                   | Tetracycline      | 4           | Resistant            | NA                   |
|                   | Tigecycline       | 1           | Susceptible          | NA                   |
| Phenicolines      | Chloramphenicol   | ≥ 64        | Resistant            | NA                   |
|                   | Trimethoprim/ Skillomides | ≥ 64 | Resistant            | NA                   |

NA, not applicable. †, Beta-lactamase gene, ‡, Oxacillinase gene, ††, New Delhi metallo-beta-lactamase-1 gene, ¶, Imipenemasegenae, †††, Oxacillinase-48 gene, ‡‡, Data reported by Michodigini et al. (2021).††

**Table 2** Spectrum of activity of individual *Klebsiella* phages isolated from Ruai and Rongai in February 2021 (CPRSA, CPRSB and ESBLA) and phage cocktail (2φ MA and 3φ MB) on reference strains and different bacterial species.

| *Klebsiella* phage | MRSA NCTC 12493 | S. aureus NCTC 1312 | S. aureus NCTC 6571 | *E. coli* NCTC 13353 | *E. coli* NCTC 12202 | *E. coli* ATCC 25922 | *P. aeruginosa* ATCC 27850 | *K. pneumoniae* NCTC 13438 | K2 | K3 | K13 | K16 | K20 (KP20) | K4 | K15 |
|--------------------|-----------------|---------------------|---------------------|----------------------|----------------------|----------------------|---------------------------|-----------------------------|----|----|-----|-----|----------|----|-----|
| CPRSA              | NS              | NS                  | NS                  | NS                   | NS                   | NS                   | NS                        | NS                          | NS | NS | NS  | NS  | NS       | NS | NS  |
| CPRSB              | NS              | NS                  | NS                  | NS                   | NS                   | NS                   | NS                        | NS                          | NS | NS | NS  | NS  | NS       | NS | NS  |
| ESBLA              | NS              | NS                  | NS                  | NS                   | NS                   | NS                   | NS                        | NS                          | NS | NS | NS  | NS  | NS       | NS | NS  |
| 2φ MA†             | NS              | NS                  | NS                  | NS                   | NS                   | NS                   | NS                        | NS                          | NS | NS | NS  | NS  | INT      | NS | NS  |
| 3φ MB‡             | NS              | NS                  | NS                  | NS                   | NS                   | NS                   | NS                        | NS                          | NS | NS | NS  | NS  | INT      | NS | NS  |
Host range of *Klebsiella* phage lysates

*Klebsiella* phages CPRSA, CPRSB and ESBLA were used for the formulation of the two-phage cocktail (2φ MA) and the three-phage cocktail (3φ MB). The two-phage cocktail comprised CPRSA and CPRSB while the three-phage cocktail consisted of CPRSA, CPRSB and ESBLA. The two-phage cocktail was the combination of two bacteriophages belonging to the family *Myoviridae* while the three-phage cocktail was the combination of 2φ MA and one belonging to the family *Podoviridae*. The results of the host range analysis showed that both the individual phages and phage cocktails (2φ MA and 3φ MB) were active on bacterial strains belonging to *Klebsiella* species. The three carbapenem-resistant *K. pneumoniae* were susceptible to only one individual phage, the *Klebsiella* phage CPRSA. The two-phage preparations were also active on the three CP *K. pneumoniae* strains, in addition to K2, which was described as an extended-spectrum beta-lactamase producer in our previous study.

Inhibitory activity of individual *Klebsiella* phages and phage cocktails on carbapenemase-producing *Klebsiella pneumoniae* culture

The ability of the mixture of two phages (MA) and three phages (3φ MB) to inhibit the growth of KP20 culture at an absorbance of ≈ 0.3 was determined at three different multiplicities of infection (MOI 1.0, 0.1 and 0.001). It was observed in our study that there was an increase in CP *K. pneumoniae* growth to the individual phage CPRSB at its three different doses and to the phage CPRSA at MOIs 0.1 and 0.001 after 8 h and 16 h of incubation (Figure 2a). The two-phage combination (2φ MA) was able to control the rapid growth of CP *K. pneumoniae* after 16 h of incubation and up to 24 h (Figure 2b). This bactericidal activity of the phage cocktail was observed at MOIs 0.1 and 0.001 whereas the three-phage cocktail (3φ MB) could slightly control the increase in CP *K. pneumoniae* growth after 16 h and at MOIs 1.0 and 0.001. At MOIs 0.1 and 0.001, the dose response of the two-phage cocktail was not significantly different in the ability to inhibit the bacterial growth at this incubation time (p = 0.105). At the most effective phage dose (MOI: 0.001), the absorbances at 600 nm of the bacterial culture treated with the individual phage CPRSA, and the two-phage cocktail (2φ MA), increased from 0.019 to 0.515, and 0.173 to 0.246 at 16 h and 20 h, while it rose from 2.116 to 2.190 for the positive control during the same interval of time (Figure 2b). For the most active individual phage (CPRSA) and phage cocktail (2φ MA), the dose responses were not significant (p = 0.12) at MOI 0.1 after 16 h of treatment time (Table 3). Significant difference (p = 0.01) was observed between the two treatments at MOI 0.001.

Interactive properties between the phage cocktails and antibiotics combinations in inhibiting the growth of carbapenemase-producing *Klebsiella pneumoniae* in vitro

The in vitro studies showed that the same phage cocktails (2φ MA and 3φ MB) maintained their bactericidal activity after 24 h of incubation at the lowest phage concentration (MOI 0.001) (Figure 3a). At different timepoints of 18 h and 24 h, the optical density at 600 nm of the bacterial culture...
treated with 2φ MA decreased from 0.217 to 0.186 whereas it increased from 0.226 to 0.269 for bacterial culture treated with 3φ MB. The results of the adjunctive treatment (phage and antibiotic combination therapy) experiments revealed that the absorbance of the bacterial culture treated with the combination of imipenem and two-phage cocktail (IMP2 + 2φ MA) decreased from 0.256 (21 h) to 0.099 (24 h) at the lowest phage concentration (Figure 3b). When the phage cocktails were combined with tigecycline, the OD600nm decreased from 0.294 (21 h) to 0.189 (24 h) for bacterial culture treated with tigecycline and the two-phage preparation at the lowest phage concentration, MOI 0.001 (TG1 + 2φ MA3) while it increased slightly from 0.207 (21 h) to 0.331 (24 h) in the case of IMP2 + 3φ MB.

### TABLE 3: Statistical significance between the concentrations of individual phages (CPRSA and CPRSB) and phage cocktails (2φ MA and 3φ MB), Nairobi, Kenya, February 2021 – October 2021.

| Treatment | p       |
|-----------|---------|
| CPRSA2† vs CPRSA3‡ | 0.11** |
| CPRSB2 vs CPRSB3 | 0.008* |
| 2φ MA2 vs CPRSA2 | 0.01* |
| 2φ MA3 vs CPRSA3 | 0.12** |
| 2φ MA2 vs 2φ MA3 | 0.10** |
| 3φ MB2 vs 3φ MB3 | 0.55** |

†, Significantly different; ‡, Not significant.

*Dig. 2 following the name of the phages represented MOI 0.1, †, Dig. 3 corresponded to MOI 0.001.
of bacterial culture treated with tigecycline and the three-phage preparation (TG1 + 3φ MB3). The absorbances of the bacterial culture treated with tigecycline was 0.249 (21 h) and 0.314 (24 h) while it ranged from 1.212 (21 h) to 1.245 (24 h) for the bacterial culture treated with imipenem. The positive control sample exhibited an optical density of 1.166 (21 h) and 1.270 (24 h). The level of significance between the bacterial culture treated with 2φ MA3 and the bacterial culture treated with IMP2 + 2φ MA3 after 21 h of incubation are shown in Table 4. The results of bacterial cultures treated with phage cocktail alone, and in combination with imipenem, were statistically significant compared with the result of bacterial culture treated with only imipenem (p = 0.02). No statistical difference was observed between the results of the bacterial culture treated with a combination of phage and antibiotic and those of bacterial culture treated with tigecycline alone. A significant difference (p = 0.04) was observed between the bacterial culture treated with 2φ MA at MOI 0.001 and the adjunctive therapy (bacterial culture treated with IMP2 + 2φ MA3).

### Discussion

This study aimed to evaluate the therapeutic potential of formulated phage cocktails and their interaction with select antibiotics in inhibiting the growth of the KP20 clinical isolate. On one hand, the phenotypic results revealed that the precipitated phages obtained in this study had lytic activity on K. pneumoniae and noncontractile tails (61%); Podoviridae having short tails (14%).

**Klebsiella**-tailed phages identified in our study belonged to the family of Myoviridae and Podoviridae. Previous studies reported similar observations regarding the morphological characters of *Klebsiella* phages.

On the other hand, this study showed that one of the precipitated phages (CPRS-A) had the shortest latency period (9 min) and high burst size (610). Our findings were supported by Horváth et al. in 2020. The authors reported that their isolated *Klebsiella* phage had a relatively short latency period of 18 min and its burst size was ~220 phage particles per infected bacteria. Indeed, a high burst size is key to achieve a productive adsorption and replication of bacteriophages and to reach the benefits that phages could have in comparison with antibiotics while a short latency period is recommended from a phage therapy perspective.

Both the individual bacteriophages and phage cocktails were not susceptible to the reference bacterial strains tested in this study and, hence, displayed high specificity for their host bacteria, which were KP20 clinical isolates. Previous studies on host ranges of *Klebsiella* phages reported similar results. The major consequence of phage host specificity is that it demands an appropriate diagnosis of the bacteria involved in the infection before initiation of phage treatment. Nevertheless, this narrowness of phage host range to the strains of the same bacterial species could limit its lytic activity on microbiota. The phage host range is indeed affected by a number of factors including the absence of required accessory proteins for phage adsorption, restriction-modification and clustered regularly interspaced short palindromic repeats (CRISPR) systems. Despite their narrow host range, bacteriophages with lytic activity may still be useful in phage therapy and the use of bacteriophages as cocktails for adjunctive treatment can represent a highly attractive strategy.

Besides the choice of bacteriophages with different bacterial cell wall receptor recognition sites in formulating a phage cocktail, the most important criterion for successful phage cocktail preparation also includes the compatibility of bacteriophages in mixtures. Therefore, our study demonstrated that the mixture of two phages (2φ MA) was able to significantly delay the resurgence of bacterial cells in culture, as compared to the application of individual phage or the mixture of three phages (3φ MB) (p = 0.02). Our result was in line with the previous data published on phage cocktail efficacy. This synergistic activity of two-phage cocktail over the mixture of three phages in our study suggested that the individual phages might have employed different receptors to adsorb to the bacterial cells and, hence, effectively inhibited the bacterial growth. Some authors have reported that one phage in their two-phage cocktail used an outer membrane protein (OmpC) as a receptor, and another one employed a lipopolysaccharide component as its receptor to effectively control bacterial resistance. Moreover, the mixture of many phages may be less effective in the absence of identification of specific bacteriophage receptors because the same phages might share the same receptors and interfere with one another.

The adjunctive treatment (IMP2 + 2φ MA3) significantly inhibited the growth of KP20 in vitro compared to the two-phage treatment alone (p = 0.04). At MOI 0.001, the two-phage cocktail combined with imipenem had significantly lysed the bacterial cell compared to the two-phage cocktail. This statistical difference might be related to the beneficial effect of bacteriophage treatment in adjunctive therapy. Our finding contradicted the study of Pacios et al., who indicated the inability of phage-imipenem combination to kill imipenem-resistant isolate harbouring OXA-245 b-lactamase. This divergence might be related to the use of a single lytic phage in adjunctive treatment instead of phage cocktail. Furthermore, an antibacterial effect was also

---

**TABLE 4: Level of significance between bacterial culture treated with two-phage cocktail and the bacterial culture treated with two-phage cocktail and imipenem combination, Nairobi, Kenya, February 2021 – October 2021.**

| Treatment                          | p     |
|-----------------------------------|-------|
| IMP21 vs 2φ MA3                   | 0.02* |
| IMP2 vs IMP2 + 2φ MA3             | 0.02* |
| 2φ MA3 vs IMP2 + 2φ MA3           | 0.04* |

*Significantly different.

1, Digit 2 represented double of the volume of imipenem at MIC = 4µg/mL, ‡, Digit 3 corresponded to MOI 0.001 of the two-phage cocktail.
observed between the phage cocktails in combination with the most effective antibiotic (tigecycline) without significant difference (p = 0.99). A number of studies have reported the positive effect of bacteriophages in combination with antibiotics. 39 This synergistic activity between phage cocktail in combination with imipenem might have been due to the sensitivity of the bacterial strains to the select antibiotic after bacteriophage action. Indeed, it was reported in a previous study that phage-resistant bacterial strains are more susceptible to antibiotics and the rate of their growth is slower in comparison with wild bacterial strains. 40 Our study also demonstrated the efficacy of phage cocktail in the absence of phage receptor analysis in formulating phage cocktails. Interestingly, this study pointed out the repurposing of imipenem using phage cocktail therapy, and further encourages the repurposing of the efficacy of Food and Drug Administration-approved antibiotics for acceptance of phage therapy worldwide, especially in Africa.

**Limitations**

The limitation of this study was the absence of genomics, which could enable us to further conclude on the taxonomic classification of the bacteriophages. The conclusions were made based on a single carbapenem-resistant strain, which was also a limiting factor in our study due to the high host specificity of phages, and the diverse *K. pneumoniae* strain types and resistance mechanisms which may affect the utility of the adjunctive therapy. The potential impact of phages on the normal microbiota was not considered in the current study, especially given that the phage cocktails might have activity against *K. pneumoniae* strains other than those that are carbapenem-resistant, and *E. coli* strains.

**Conclusion**

This current study revealed the presence of lytic tailed *Klebsiella* phages belonging to the family *Myoviridae, Siphoviridae and Podoviridae* in Nairobi sewage systems with relatively short latent periods and optimal burst sizes, indicating their therapeutic potential in composing phage cocktails and synergistic interaction in combination with non-sensitive antibiotic (imipenem) against carbapenem-resistant *K. pneumoniae* clinical isolate in vitro.

**Acknowledgements**

We are grateful to the Pan African University under the African Union for financial support. We are thankful to Ms Ivy Mutai, Angela Juma, Mercy Munini and Mr Dennis Kotty for their collaboration on phage isolation. Our gratitude to Dr Jessica Sacher of the Phage Directory for having facilitated the transmission electron microscope analysis.

**Competing interests**

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

**Authors’ contributions**

N.F.M., A.N., J.K.A., G.M. and A.N.K. conceived and designed the study. N.F.M. conducted the laboratory experiments, data analysis and drafted the original manuscript. N.F.M., A.N., J.K.A., G.M. and A.-S.O. reviewed and approved the final manuscript for submission.

**Sources of support**

This research project was supported by the Pan African University.

**Data availability**

All data are available from the corresponding author, N.F.M., upon request.

**Disclaimer**

The views and opinions expressed in this article are only those of the authors.

**References**

1. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. https://doi.org/10.1016/S1473-3099(17)30753-3
2. Seykatawa K, Byarugabe DK, Wampande E, Ejobi F. A systematic review: The current status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11(1):1–9. https://doi.org/10.1186/s13104-018-3738-2
3. Inal JM. Phage therapy: A reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp. 2003;51(4):237–244.
4. Li M, Yao Y, Li P, et al. Characterization and genome analysis of Klebsiella phage PS09, with lytic activity against clinical carbapenem – Resistant Klebsiella pneumoniae of the K164 capsular type. Arch Virol. 2020;165:2799–2806. https://doi.org/10.1007/s00705-020-02482-0
5. Cao F, Wang X, Wang L, et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res. 2015;2015:752930. https://doi.org/10.1155/2015/752930
6. Drulis-kawa Z, Majkowska-skrøbek G, Maciejewska B, Delatelle A, Lavigne R. Learning from bacteriophages – Advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci. 2012;13(8):699–722. https://doi.org/10.2174/13892031280471193
7. Loc-carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111–114. https://doi.org/10.4161/bact.1.2.14590
8. Knezec P, Hoyle NS, Matsuoka S, Gorski A. Editorial: Advances in phage therapy: Present challenges and future perspectives. Front Cell Infect Microbiol. 2021;12:1390. https://doi.org/10.3389/fmicb.2021.701898
9. Iszatt JJ, Larcombe AN, Chan H, Stick SM, Garratt UW, Kicic A. Phage therapy for multi-drug resistant respiratory tract infections. Viruses. 2021;13(9):1809. https://doi.org/10.3390/v13091809
10. Abd-Allah IM, El-houssein GS, Yahia IS. Rekindling of a masterful precedent: bacteriophage: Reappraisal and future pursuits. Front Cell Infect Microbiol. 2021;11:47. https://doi.org/10.3389/fcimb.2021.635597
11. Chan BK, Abedon ST, Loc-carrillo C. Phage cocktails and the future of phage therapy. Futur Microbiol. 2013;8(6):769–783. https://doi.org/10.2217/fmb.13.147
12. Makumi A, Mhone AL, Odaba J, Guantai L, Svitík N. Phages for Africa: The potential benefit and challenges of phage therapy for the livestock sector in sub-Saharan Africa. Antibiotics. 2021;10(9):1085. https://doi.org/10.3390/antbiot10091085
13. Michodigni NF, Nyachieo A, Akhwale JK, Magoma G. Molecular identification of co-existence of carbapenemase and extended-spectrum β-lactamase genes in Klebsiella pneumoniae clinical isolates, and their phylogenetic patterns in Kenya. Adv Microbiol. 2021;11(8):399–415. https://doi.org/10.4236/am.2021.118030
14. Gutiérrez D, Fernández I, Rodríguez A, García P. Practical method for isolation of phage deletion mutants. Methods Protoc. 2018;11(1):6. https://doi.org/10.3390/mpe11010006
15. Odur IMO, Onkoba N, Maloba F, Nyachieo A. Experimental phage therapy against haematogenous multi-drug resistant *Staphylococcus aureus pneumonia in mice*. Afr J Lab Med. 2016;5(1):1–7. https://doi.org/10.4102/ajlm.v5i1.435
16. Pajunen M, Kijlunen S, Skurnik M, Molinieux I, Molinieux I. Bacteriophage φYeO3-12, specific for *Yersinia enterocolitica* Serotype O: 3, is related to coliphages T3 and T7 this study. Am Soc Microbiol. 2000;182(18):5114–5120. https://doi.org/10.1128/ajas.182.18.5114-5120.2000
17. Haines MEK, Hodges FE, Nale JV, et al. Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria. Front Med. 2021;12:613529. https://doi.org/10.3389/fmedic.2021.613529

18. Bradley DE. Ultrastructure of bacteriophages and bacteriocins. Am Soc Microbiol. 1967;31.230–314. https://doi.org/10.1128/br.31.4.230-314.1967

19. Kutter E. Isolation, characterization, and interactions. In: Martha RJ, Clokie AMK, editors. Bacteriophages: Methods and protocols. Volume I. Rijeka: Springer Science+Business Media; 2014. p. 143–148.

20. Horváth M, Kovács T, Koderivalappil S, Ábrahám H. Identification of a newly isolated lytic bacteriophage against Klebsiella pneumoniae K24 capsular type, carbapenem-resistant Klebsiella pneumoniae isolates. Sci Rep. 2020;10:1–11. https://doi.org/10.1038/s41598-020-62691-8

21. Baer A, Kehn-Hall K. Viral concentration determination through plaque assays: Using traditional and novel overlay systems. J Vis Exp. 2014;(93):e52065. https://doi.org/10.3791/52065

22. Merabishvili M, Pimay J, De Vos D. Guidelines to compose an ideal bacteriophage cocktail. In: Siliskorva JÁS, editor. Bacteriophage therapy. Rijeka: Springer Science and Business Media LLC; 2018. p. 99–109.

23. Ackermann H. Bacteriophage observations and evolution. Res Microbiol. 2003;154(4):245–251. https://doi.org/10.1016/S0923-2508(03)00067-6

24. White HE, Orlova EV. Biology and applications. In: Savva RS, editor. Bacteriophages. Science and Business Media LLC; 2018. p. 99–109.

25. Gao M, Wang C, Qiang X, et al. Isolation and characterization of a novel bacteriophage infecting carbapenem-resistant Klebsiella pneumoniae. Biotechnol Lett. 2018;40(4):1–11. https://doi.org/10.1007/s10529-017-9346-1

26. Mirzei MK, Nilsson AS. Isolation of phages for phage therapy: A comparison of different methods. Viruses. 2018;10(4):189. https://doi.org/10.3390/v10040189

27. Labrie SJ, Samson JE, Mineau S. Bacteriophage resistance mechanisms. Nat Publ Gr. 2010;8:317–327. https://doi.org/10.1038/nrmicro2315

28. Bhetwal A, Maharjan A, Shakya S, et al. Isolation of potential phages against multidrug-resistant bacterial isolates: Promising agents in the rivers of Kathmandu, Nepal. BioMed Res Internantional. 2017;2017:3723254. https://doi.org/10.1155/2017/3723254

29. Domingo-Calap P, Beumud B, Vienne J, González-Candelas F, Sanjuan R. Isolation of four lytic phages infecting Klebsiella pneumoniae K22 clinical isolates from Spain. Int J Mol Sci. 2020;21:425. https://doi.org/10.3390/ijms21020425

30. Skurnik M, Pajunen A, Kiljunen AS. Biotechnological challenges of phage therapy. Biotechnol Lett. 2007;29(7):995–1003. https://doi.org/10.1007/s10529-007-9346-1

31. Xie Y, Wahab LGI. Development and validation of a microtiter plate-based assay for determination of bacteriophage host range and virulence. Viruses. 2018;10(4):189. https://doi.org/10.3390/v10040189

32. Li X, He Y, Wang Z, et al. A combination therapy of phages and antibiotics: Two is better than one. Int J Biol Sci. 2021;17(13):3573–3582. https://doi.org/10.7150/ijbs.60551

33. Domingo-Calap P, Beumud B, Vienne J, González-Candelas F, Sanjuan R. Isolation of four lytic phages infecting Klebsiella pneumoniae K22 clinical isolates from Spain. Int J Mol Sci. 2020;21:425. https://doi.org/10.3390/ijms21020425

34. Paulo L, Carla A, Angela C, Romalde L, Nunes ML. Bacteriophages with potential to inactivate Salmonella Typhimurium: Use of. Virus Res. 2016;220:179–192. https://doi.org/10.1016/j.viruses.2016.04.020

35. Tanji Y, Shimada T, Yoichi M, Miyanaga K, Hori K, Unno H. Toward rational control of Escherichia coli O157: H7 by a phage cocktail. Appl Microbiol Biotechnol. 2004;63:270–274. https://doi.org/10.1007/s00253-003-1438-9

36. Goodridge LD. Designing phage therapeutics. Curr Pharm Biotechnol. 2010;11(1):15–27. https://doi.org/10.2174/138920110790725348

37. Hall AR, De Vos D, Friman V, Pirnay J, Buckling A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth. Appl Environ Microbiol. 2012;78(16):5646–5652. https://doi.org/10.1128/AEM.00757-12

38. Pacios O, Fernández-garcía L, Blorter I, Blasco L, González-bardanca M, López M. Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage VB - KpnM- VAC13 against clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021;65(9):e0090021. https://doi.org/10.1128/AAC.00900-21

39. Li X, He Y, Wang Z, et al. A combination therapy of phages and antibiotics: Two is better than one. Int J Biol Sci. 2021;17(13):3573–3582. https://doi.org/10.7150/ijbs.60551

40. Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10(7):351. https://doi.org/10.3390/v10070351